Drug Profile

EDP 297

Alternative Names: EDP-297

Latest Information Update: 30 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Enanta Pharmaceuticals
Developer Enanta Pharmaceuticals; PRA Health Sciences
Class Hepatoprotectants; Small molecules
Mechanism of Action Farnesoid X-activated receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Non-alcoholic steatohepatitis

Most Recent Events

30 Aug 2022 3697877: KDM updated, clinical data added
22 Jun 2022 Adverse events and pharmacokinetics data from a phase I trial in Non-alcoholic steatohepatitis presented at The International Liver Congress 2022 (ILC-2022)
22 Nov 2021 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in Netherlands (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com